Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register

• Published in: Diabetes research and clinical practice Vol. 202; p. 110825
• Main Authors: Kong, Alice Pik-Shan, Lau, Eric Siu-Him, O, Chun-Kwan, Luk, Andrea On-Yan, Yip, Terry Cheuk-Fung, Chow, Elaine Yee-Kwan, Kwok, Raymond, Lee, Hye Won, Wong, Grace Lai-Hung, Ma, Ronald Ching-Wan, Chan, Henry Lik-Yuen, Wong, Vincent Wai-Sun, Chan, Juliana Chung-Ngor
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01-08-2023
• Subjects: Heart failure; Hospitalization; Mortality; NAFLD; NASH; Type 2 diabetes; Type 2 diabetes; Heart failure; NAFLD; Hospitalization; NASH; Mortality
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2023.110825

We aimed to examine the impact of non-alcoholic fatty liver disease (NAFLD) on the clinical outcomes in patients with type 2 diabetes (T2D).
Between 2013 and 2014, 1,734 patients with T2D underwent transient elastography (TE) to assess liver status indicated by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). Liver steatosis was defined by CAP ≥ 248 dB/m and advanced liver fibrosis by LSM ≥ 10 kPa. In 2019, we assessed their clinical outcomes including hospitalizations and mortality.
In this prospective cohort [56% men, mean (±standard deviation) age:60.8±11.5 years; glycated hemoglobin (HbA1c)7.8±1.6 %], 798 patients had liver steatosis, 296 patients had advanced liver fibrosis and 640 patients had normal liver at baseline. T2D with advanced liver fibrosis had higher body mass index, waist circumference, waist-hip ratio, fasting plasma glucose, HbA1c, blood pressure and lipid profiles than their counterparts with NAFLD or normal liver (all p < 0.05). After a median follow-up of 6.07 (interquartile range:5.84 to 6.30) years, there were 4,403 incident hospitalizations, 32,119 days of hospital stay, and 171 deaths. Using Cox regression analysis, advanced liver fibrosis was associated with increased risk of heart failure (hazard ratio [95% confidence interval] HR:3.07[1.08–8.68], p=0.035) and hospitalizations (HR:1.39[1.14–1.70], p=0.001) while liver steatosis was associated with reduced mortality (HR:0.60[0.41–0.87], p=0.007) compared to their counterparts with normal liver after adjustment for potential confounders.
T2D comorbid with liver steatosis and advanced liver fibrosis are distinct clinical entities with differences in outcomes. Advanced liver fibrosis is an important predictor for worse outcomes including heart failure and hospitalizations in people with T2D.